Company registration number 01233986 (England and Wales)
LAMINAR MEDICA LIMITED
FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
PAGES FOR FILING WITH REGISTRAR
LAMINAR MEDICA LIMITED
CONTENTS
Page
Balance sheet
1
Statement of changes in equity
2
Notes to the financial statements
3 - 11
LAMINAR MEDICA LIMITED
BALANCE SHEET
AS AT
31 DECEMBER 2025
31 December 2025
- 1 -
2025
2024
Notes
£
£
£
£
Fixed assets
Tangible assets
3
666,959
865,624
Investments
4
9,781
4,749
676,740
870,373
Current assets
Stocks
490,152
555,184
Debtors
6
1,340,434
5,943,019
Cash at bank and in hand
1,023,016
11,908
2,853,602
6,510,111
Creditors: amounts falling due within one year
7
(776,246)
(575,028)
Net current assets
2,077,356
5,935,083
Total assets less current liabilities
2,754,096
6,805,456
Provisions for liabilities
8
(625,000)
(81,958)
Net assets
2,129,096
6,723,498
Capital and reserves
Called up share capital
9
250,200
250,200
Profit and loss reserves
1,878,896
6,473,298
Total equity
2,129,096
6,723,498

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The directors of the company have elected not to include a copy of the profit and loss account within the financial statements.true

The financial statements were approved by the board of directors and authorised for issue on 25 September 2026 and are signed on its behalf by:
Gary Morgan
Director
Company registration number 01233986 (England and Wales)
LAMINAR MEDICA LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 DECEMBER 2025
- 2 -
Share capital
Profit and loss reserves
Total
Notes
£
£
£
Balance at 1 January 2024
250,200
6,752,573
7,002,773
Year ended 31 December 2024:
Loss and total comprehensive income
-
(279,275)
(279,275)
Balance at 31 December 2024
250,200
6,473,298
6,723,498
Year ended 31 December 2025:
Loss and total comprehensive income
-
(594,402)
(594,402)
Dividends
-
(4,000,000)
(4,000,000)
Balance at 31 December 2025
250,200
1,878,896
2,129,096
LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 DECEMBER 2025
- 3 -
1
Accounting policies
Company information

Laminar Medica Limited is a private company limited by shares incorporated in England and Wales. The registered office is 27 Old Gloucester Street, London, England, WC1N 3AX.

1.1
Basis of preparation

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention. The principal accounting policies adopted are set out below.

1.2
Going concern

Atruet the time of approving the financial statements, the directors have a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future. Thus the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

 

With the completed sale of the business the directors do not anticipate any changes to the existing strategic plans and the current structure will remain intact. Furthermore, the directors are confident the business remains well placed to develop and continue trading for the foreseeable future.

1.3
Revenue

Turnover represents the value of goods sold excluding value added tax. Turnover is recognised at the point of despatch of non-returnable goods to customers. Turnover is disclosed gross of carriage costs.

Revenue from the sale of goods is recognised when the significant risks and rewards of ownership of the goods have passed to the buyer (usually on dispatch of the goods), the amount of revenue can be measured reliably, it is probable that the economic benefits associated with the transaction will flow to the entity and the costs incurred or to be incurred in respect of the transaction can be measured reliably.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
Over the lease term
Plant and equipment
Over 3 to 10 years

No depreciation is charged on assets under construction.

 

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 4 -
1.5
Fixed asset investments

Interests in subsidiaries, associates and jointly controlled entities are initially measured at cost and subsequently measured at cost less any accumulated impairment losses. The investments are assessed for impairment at each reporting date and any impairment losses or reversals of impairment losses are recognised immediately in profit or loss.

A subsidiary is an entity controlled by the company. Control is the power to govern the financial and operating policies of the entity so as to obtain benefits from its activities.

An associate is an entity, being neither a subsidiary nor a joint venture, in which the company holds a long-term interest and where the company has significant influence. The company considers that it has significant influence where it has the power to participate in the financial and operating decisions of the associate.

Entities in which the company has a long term interest and shares control under a contractual arrangement are classified as jointly controlled entities.

1.6
Impairment of fixed assets

At each reporting period end date, the company reviews the carrying amounts of its tangible assets to determine whether there is any indication that those assets have suffered an impairment loss. If any such indication exists, the recoverable amount of the asset is estimated in order to determine the extent of the impairment loss (if any). Where it is not possible to estimate the recoverable amount of an individual asset, the company estimates the recoverable amount of the cash-generating unit to which the asset belongs.

Recoverable amount is the higher of fair value less costs to sell and value in use. In assessing value in use, the estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset for which the estimates of future cash flows have not been adjusted. If the recoverable amount of an asset (or cash-generating unit) is estimated to be less than its carrying amount, the carrying amount of the asset (or cash-generating unit) is reduced to its recoverable amount. An impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the impairment loss is treated as a revaluation decrease.

Recognised impairment losses are reversed if, and only if, the reasons for the impairment loss have ceased to apply. Where an impairment loss subsequently reverses, the carrying amount of the asset (or cash-generating unit) is increased to the revised estimate of its recoverable amount, but so that the increased carrying amount does not exceed the carrying amount that would have been determined had no impairment loss been recognised for the asset (or cash-generating unit) in prior years. A reversal of an impairment loss is recognised immediately in profit or loss, unless the relevant asset is carried at a revalued amount, in which case the reversal of the impairment loss is treated as a revaluation increase.

1.7
Stocks

Stocks are stated at the lower of cost and estimated selling price less costs to complete and sell. Cost comprises direct materials and, where applicable, direct labour costs and those overheads that have been incurred in bringing the stocks to their present location and condition.

 

Stocks held for distribution at no or nominal consideration are measured at the lower of cost and replacement cost, adjusted where applicable for any loss of service potential.

At each reporting date, an assessment is made for impairment. Any excess of the carrying amount of stocks over its estimated selling price less costs to complete and sell is recognised as an impairment loss in profit or loss. Reversals of impairment losses are also recognised in profit or loss.

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 5 -
1.8
Cash and cash equivalents

Cash and cash equivalents are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Basic financial assets

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

Classification of financial liabilities

Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the company after deducting all of its liabilities.

Basic financial liabilities

Basic financial liabilities, including creditors, bank loans, loans from fellow group companies and preference shares that are classified as debt, are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

 

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

 

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of transaction costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 6 -
Current tax

Current tax is the amount of income tax payable in respect of the taxable profit for the year or prior years. Tax is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the period end.

 

Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation. It establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.

 

 

Deferred tax

Deferred tax arises from timing differences between taxable profits and total comprehensive income as stated in the financial statements. These timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements.

 

Deferred tax is recognised on all timing differences at the reporting date except for certain exceptions. Unrelieved tax losses and other deferred tax assets are only recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

 

Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the period end and that are expected to apply to the reversal of the timing difference.

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Provisions

Provisions are recognised when the company has a legal or constructive present obligation as a result of a past event, it is probable that the company will be required to settle that obligation and a reliable estimate can be made of the amount of the obligation.

 

The amount recognised as a provision is the best estimate of the consideration required to settle the present obligation at the reporting end date, taking into account the risks and uncertainties surrounding the obligation. Where the effect of the time value of money is material, the amount expected to be required to settle the obligation is recognised at present value. When a provision is measured at present value, the unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
1
Accounting policies
(Continued)
- 7 -
1.13
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.14
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

 

1.15
Leases
As lessee

Rentals payable under operating leases, including any lease incentives received, are charged to profit or loss on a straight line basis over the term of the relevant lease except where another more systematic basis is more representative of the time pattern in which economic benefits from the leases asset are consumed.

1.16
Foreign exchange

Foreign currency transactions are translated into the functional currency using the spot exchange rates at the dates of transactions.

 

At each period end foreign currency monetary items are translated using the closing rate. Non-monetary items measured at historical cost are translated using the exchange rate at the date of the transaction and non-monetary items measured at fair value are measured using the exchange rate when the fair value was determined.

 

Foreign exchange gains and losses resulting from the settlement of transactions and from the translation at period-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in the profit and loss account.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2025
2024
Number
Number
Total
40
42
LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 8 -
3
Tangible fixed assets
Leasehold land and buildings
Assets under construction
Plant and equipment
Total
£
£
£
£
Cost
At 1 January 2025
357,479
740
4,209,835
4,568,054
Disposals
-
0
-
0
(32,607)
(32,607)
Transfers
-
0
(740)
740
-
0
At 31 December 2025
357,479
-
0
4,177,968
4,535,447
Depreciation and impairment
At 1 January 2025
35,185
-
0
3,667,245
3,702,430
Depreciation charged in the year
14,438
-
0
164,427
178,865
Eliminated in respect of disposals
-
0
-
0
(12,807)
(12,807)
At 31 December 2025
49,623
-
0
3,818,865
3,868,488
Carrying amount
At 31 December 2025
307,856
-
0
359,103
666,959
At 31 December 2024
322,294
740
542,590
865,624
4
Fixed asset investments
2025
2024
£
£
Shares in group undertakings and participating interests
9,781
4,749
Movements in fixed asset investments
Shares in subsidiaries
£
Cost or valuation
At 1 January 2025
4,749
Valuation changes
5,032
At 31 December 2025
9,781
Carrying amount
At 31 December 2025
9,781
At 31 December 2024
4,749
5
Associates

Details of the company's associates at 31 December 2025 are as follows:

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
5
Associates
(Continued)
- 9 -
Name of undertaking
Registered office
Class of
% Held
shares held
Direct
Laminar Medica (CE) S.R.U.
Czechia
Ordinary
10.00

The registered address of Laminar Medica (CE) S.R.U is Cicenicka, 1271 38901, Vodnany, Czechia. The directors believe the carrying value of the investment is supportable by the underlying net assets of the entity.

6
Debtors
2025
2024
Amounts falling due within one year:
£
£
Trade debtors
730,347
810,070
Amounts owed by group undertakings
190,935
4,748,919
Other debtors
253,214
384,030
1,174,496
5,943,019
2025
2024
Amounts falling due after more than one year:
£
£
Deferred tax asset
165,938
-
0
Total debtors
1,340,434
5,943,019
7
Creditors: amounts falling due within one year
2025
2024
£
£
Trade creditors
292,478
190,273
Amounts owed to group undertakings
66,467
13,611
Taxation and social security
152,326
70,607
Other creditors
264,975
300,537
776,246
575,028
LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
- 10 -
8
Provisions for liabilities
2025
2024
£
£
Dilapidation provision
625,000
-
Deferred tax liabilities
-
0
81,958
625,000
81,958

The group has recognised a provision for dilapidations in respect of expected costs required to restore the leasehold property to its original condition at the end of the lease term. The provision represents management's best estimate of the obligation arising under the lease agreement.

9
Called up share capital
2025
2024
2025
2024
Ordinary share capital
Number
Number
£
£
Issued and fully paid
Ordinary shares of £1 each
250,200
250,200
250,200
250,200
10
Audit report information

As the income statement has been omitted from the filing copy of the financial statements, the following information in relation to the audit report on the statutory financial statements is provided in accordance with s444(5B) of the Companies Act 2006.

The auditor's report was unqualified.

Senior Statutory Auditor:
Alexander Kelly BA FCA
Statutory Auditor:
MHA
Date of audit report:
25 September 2026
11
Operating lease commitments
As lessee

At the reporting end date the company had outstanding commitments for future minimum lease payments under non-cancellable operating leases, as follows:

2025
2024
£
£
Total commitments
66,000
291,000
12
Parent company

The Company’s immediate holding company is Arctic UK Bidco Limited, which is registered in England and Wales.

LAMINAR MEDICA LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 DECEMBER 2025
12
Parent company
(Continued)
- 11 -

Until 3 November 2025, the Company's immediate parent company was Sonoco Cores and Paper Limited, with the ultimate controlling party being Sonoco Products Company, incorporated in the United States of America. Copies of the ultimate parent’s consolidated financial statements which is the smallest and largest company to consolidate these financial statements may be obtained from: The Secretary, Sonoco Products Company, Hartsville, South Carolina 29550, USA.

 

On 3 November 2025, Arctic US Bidco Inc. completed the acquisition of the ThermoSafe business unit, including Laminar Medica Limited. The new ultimate controlling party is Arsenal Capital Group LLC. The largest and smallest group in which the results of the company are consolidated is Arsenal Capital Group LLC. These consolidated financial statements are not publicly available.

 

 

2025-12-312025-01-01falsefalsefalse25 September 2026CCH SoftwareCCH Accounts Production 2026.100No description of principal activityStacy WilliamsGary MorganEnda McGuireFilippo LamonacaJames Lassiter JrAndrew SinnenElemental CoSec Limited012339862025-01-012025-12-31012339862025-12-31012339862024-12-3101233986core:LongLeaseholdAssets2025-12-3101233986core:ConstructionInProgressAssetsUnderConstruction2025-12-3101233986core:PlantMachinery2025-12-3101233986core:LandBuildings2024-12-3101233986core:ConstructionInProgressAssetsUnderConstruction2024-12-3101233986core:PlantMachinery2024-12-3101233986core:CurrentFinancialInstrumentscore:WithinOneYear2025-12-3101233986core:CurrentFinancialInstrumentscore:WithinOneYear2024-12-3101233986core:CurrentFinancialInstruments2025-12-3101233986core:CurrentFinancialInstruments2024-12-3101233986core:ShareCapital2025-12-3101233986core:ShareCapital2024-12-3101233986core:RetainedEarningsAccumulatedLosses2025-12-3101233986core:RetainedEarningsAccumulatedLosses2024-12-3101233986core:ShareCapital2023-12-3101233986core:RetainedEarningsAccumulatedLosses2023-12-3101233986core:ShareCapitalOrdinaryShareClass12025-12-3101233986core:ShareCapitalOrdinaryShareClass12024-12-3101233986bus:Director22025-01-012025-12-3101233986core:RetainedEarningsAccumulatedLosses2024-01-012024-12-31012339862024-01-012024-12-3101233986core:RetainedEarningsAccumulatedLosses2025-01-012025-12-3101233986core:LandBuildingscore:LongLeaseholdAssets2025-01-012025-12-3101233986core:PlantMachinery2025-01-012025-12-3101233986core:LandBuildingscore:LeasedAssetsHeldAsLessee2024-12-3101233986core:ConstructionInProgressAssetsUnderConstruction2024-12-3101233986core:PlantMachinery2024-12-31012339862024-12-3101233986core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-12-3101233986core:LandBuildingscore:LeasedAssetsHeldAsLessee2025-01-012025-12-3101233986core:ConstructionInProgressAssetsUnderConstruction2025-01-012025-12-3101233986core:Associate12025-01-012025-12-3101233986core:Associate112025-01-012025-12-3101233986core:AfterOneYear2025-12-3101233986core:AfterOneYear2024-12-3101233986bus:OrdinaryShareClass12025-12-3101233986bus:OrdinaryShareClass12024-12-3101233986bus:PrivateLimitedCompanyLtd2025-01-012025-12-3101233986bus:SmallCompaniesRegimeForAccounts2025-01-012025-12-3101233986bus:FRS1022025-01-012025-12-3101233986bus:Audited2025-01-012025-12-3101233986bus:Director12025-01-012025-12-3101233986bus:Director32025-01-012025-12-3101233986bus:Director42025-01-012025-12-3101233986bus:Director52025-01-012025-12-3101233986bus:Director62025-01-012025-12-3101233986bus:CompanySecretary12025-01-012025-12-3101233986bus:FullAccounts2025-01-012025-12-31xbrli:purexbrli:sharesiso4217:GBP